枯草杆菌联合标准三联疗法治疗幽门螺杆菌感染临床疗效

发布时间：2018-08-19 15:07

【摘要】：目的:对枯草杆菌辅助治疗幽门螺杆菌(Helicobacter pylori,Hp)感染的临床疗效与价值进行评估。方法:选取2014年4月至2017年3月在我院消化内科门诊及病房就诊的267例符合纳入标准的Hp阳性患者,全部入组患者均被确诊功能性消化不良,除外试验2周内曾服用影响本试验观察的药物或既往有过Hp感染且根除治疗失败的患者。将所有入组患者随机分为研究组和对照组。对照组患者予以阿莫西林克拉维酸钾片、克拉霉素片和泮托拉唑肠溶片;研究组患者予以阿莫西林克拉维酸钾片、克拉霉素片、泮托拉唑肠溶片和枯草杆菌屎肠球菌二联活菌肠溶胶囊。2周后停止服用所有药物,第6周复查~(13)C尿素呼气试验。试验第1周、第2周时记录患者不良反应发生情况。比较两组的Hp根除率及不良反应发生率。结果:总根除率方面,加入了枯草杆菌屎肠球菌二联活菌肠溶胶囊的研究组为89.6%,显著高于对照组的76.5%,差异有统计学意义(P0.05);不良反应方面,研究组(6.7%)显著低于对照组(18.9%),差异有统计学意义(P0.05)。结论:应用枯草杆菌屎肠球菌二联活菌肠溶胶囊联合标准三联疗法治疗Hp感染有利于提高Hp根除率,减少不良反应的发生,改善治疗效果。
[Abstract]:Objective: to evaluate the clinical efficacy and value of subtilis in the treatment of Helicobacter pylorus HP infection. Methods: from April 2014 to March 2017, 267 HP positive patients were selected from outpatients and wards of the Department of Digestive Medicine of our hospital, all of whom were diagnosed as functional dyspepsia. Patients who had previously had HP infection and failed eradication treatment within 2 weeks were treated with drugs that affected the observation of the trial. All the patients were randomly divided into study group and control group. Patients in the control group were given amoxicillin clavulanate potassium tablets, clarithromycin tablets and pam Tora zole enteric-coated tablets, while patients in the study group received amoxicillin clavulanate potassium tablets and clarithromycin tablets. Tora enteric-coated tablets and Bacillus faecium enteric-coated capsules were stopped to take all drugs after .2 weeks, and the ~ (13) C urea breath test was reexamined at the 6th week. Adverse reactions were recorded at week 1 and week 2 of the trial. HP eradication rate and adverse reaction rate were compared between the two groups. Results: in the total eradication rate, the study group with Bacillus faecium Enterococcus faecium enteric-coated capsule was 89.6m, significantly higher than the control group 76.5g, the difference was statistically significant (P0.05); The study group (6.7%) was significantly lower than the control group (18.9%), the difference was statistically significant (P0.05). Conclusion: the treatment of HP infection with Bacillus faecium enteric-coated capsule combined with standard triple therapy can improve HP eradication rate, reduce the occurrence of adverse reactions and improve the therapeutic effect.
【作者单位】：安徽医科大学海军临床学院;中国人民解放军海军总医院消化内科;
【基金】：首都特色临床应用基金(Z16110700050000)
【分类号】：R57

【相似文献】